$43.89
5.65% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

SpringWorks Therapeutics Inc Stock price

$46.52
-6.76 12.69% 1M
+13.69 41.70% 6M
+10.39 28.76% YTD
+0.23 0.50% 1Y
-13.23 22.14% 3Y
+20.25 77.08% 5Y
+23.89 105.57% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+4.64 11.08%
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

Key metrics

Market capitalization $3.49b
Enterprise Value $3.19b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.63
P/S ratio (TTM) P/S ratio 18.20
P/B ratio (TTM) P/B ratio 7.19
Revenue growth (TTM) Revenue growth 3,417.33%
Revenue (TTM) Revenue $191.59m
EBIT (operating result TTM) EBIT $-278.13m
Free Cash Flow (TTM) Free Cash Flow $-180.05m
Cash position $307.99m
EPS (TTM) EPS $-3.48
P/E forward negative
P/S forward 10.09
EV/Sales forward 9.22
Short interest 12.14%
Show more

Is SpringWorks Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Buy
100%

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
192 192
3,415% 3,415%
100%
- Direct Costs 16 16
390% 390%
8%
176 176
7,954% 7,954%
92%
- Selling and Administrative Expenses 250 250
30% 30%
130%
- Research and Development Expense 201 201
33% 33%
105%
-275 -275
19% 19%
-143%
- Depreciation and Amortization 3.47 3.47
22% 22%
2%
EBIT (Operating Income) EBIT -278 -278
19% 19%
-145%
Net Profit -258 -258
21% 21%
-135%

In millions USD.

Don't miss a Thing! We will send you all news about SpringWorks Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SpringWorks Therapeutics Inc Stock News

Positive
Seeking Alpha
23 days ago
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children.
Neutral
GlobeNewsWire
about one month ago
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively –
Neutral
PRNewsWire
about one month ago
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient adv...
More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office United States
CEO Saqib Islam
Employees 368
Founded 2017
Website www.springworkstx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today